Jeremy M. Shefner

Jeremy M. Shefner

Neuromusculoskeletal Medicine | Neurology

240 W Thomas Rd
Ste 400
Phoenix, AZ 85013

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

Journal: JAMA neurology

Published: March 16, 2026

Evaluation of Digital Technologies for Home-Based Assessment in People With Amyotrophic Lateral Sclerosis.

Evaluation of Digital Technologies for Home-Based Assessment in People With Amyotrophic Lateral Sclerosis.

Journal: Annals of clinical and translational neurology

Published: December 23, 2025

Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial.

Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: December 17, 2025

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.

Journal: Muscle & nerve

Published: October 29, 2025

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Journal: Muscle & nerve

Published: October 29, 2025

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: June 27, 2025

Hospitalizations as an outcome measure in COURAGE-ALS.

Hospitalizations as an outcome measure in COURAGE-ALS.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: June 12, 2025

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.

Journal: Journal of neuromuscular diseases

Published: May 05, 2025

Study 19 (MCI186-19) Post Hoc Analyses.

Study 19 (MCI186-19) Post Hoc Analyses.

Journal: Muscle & nerve

Published: April 01, 2025

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.

Journal: JAMA neurology

Published: March 24, 2025

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Journal: JAMA

Published: March 11, 2025

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Journal: JAMA network open

Published: February 17, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026